Department of Neurology, Shuguang Hospital, Shanghai University of TCM, 185, Pu-An Road, Shanghai 200021, China.
Parkinsons Dis. 2011;2011:789506. doi: 10.4061/2011/789506. Epub 2011 May 17.
We evaluated the effects of a traditional Chinese medicine (TCM), named Zeng-xiao An-shen Zhi-chan 2 (ZAZ2), on patients with Parkinson's disease (PD). Among 115 patients with idiopathic PD enrolled (mean age, 64.7 ± 10.2 years old), 110 patients (M = 65, F = 45; mean age, 64.9 ± 10.7 years old) completed the study. Patients took either ZAZ2 (n = 59) or placebo granule (n = 56) in a blind manner for 13 weeks while maintaining other anti-Parkinson medications unchanged. All participants wore a motion logger, and we analyzed the power-law temporal autocorrelation of the motion logger records taken on 3 occasions (before, one week, and 13 weeks after the drug administration). Drug efficacy was evaluated with the conventional Unified Parkinson Disease Rating Scale (UPDRS), as well as the power-law exponent α, which corresponds to the level of physical activity of the patients. ZAZ2 but not placebo granule improved the awake-sleep rhythm, the UPDRS Part II, Part II + III, and Part IV scores, and the α values. The results indicate that ZAZ2 improved activities of daily living (ADL) of parkinsonism and, thus, is a potentially suitable drug for long-term use.
我们评估了一种名为增消安神止颤 2 号（ZAZ2）的中药对帕金森病（PD）患者的影响。在纳入的 115 例特发性 PD 患者中（平均年龄 64.7 ± 10.2 岁），有 110 例患者（M = 65，F = 45；平均年龄 64.9 ± 10.7 岁）完成了研究。患者以盲法服用 ZAZ2（n = 59）或安慰剂颗粒（n = 56），同时保持其他抗帕金森药物不变，持续 13 周。所有参与者都佩戴了运动记录器，我们分析了 3 次（给药前、1 周和 13 周后）记录的运动记录器的幂律时间自相关。使用传统的统一帕金森病评定量表（UPDRS）以及对应于患者身体活动水平的幂律指数α来评估药物疗效。ZAZ2 而非安慰剂颗粒改善了觉醒-睡眠节律、UPDRS 第二部分、第二部分+第三部分和第四部分评分以及α值。结果表明，ZAZ2 改善了帕金森病的日常生活活动（ADL），因此是一种适合长期使用的潜在药物。
